Review
Open access
Oct 2026
Efficacy and safety of zilebesiran for inadequately controlled hypertension: a systematic review and meta-analysis
Hypertension remains the leading modifiable risk factor for cardiovascular disease, yet control rates are suboptimal due to poor adherence and blood pressure (BP) variability with daily oral regimens. Zilebesiran is an investigational RNA interference therapeutic targeting hepatic angiotensinogen (AGT) synthesis....
T. Bonafé, G. A. Alves, B. M. Gomes et al.
· European Heart Journal · 0 citations